Antibacterial and antimicrobial therapies
Clinical research at Antibiotice S.A. includes oral and local treatments used in bacterial infections, with interest in agents such as cefixime, rifaximin, and nitrofurantoin.
- Cephalosporin antibiotics
- Urinary tract infection therapies
- Gastrointestinal antibacterial treatment
The sponsor’s research portfolio also covers comparative assessment of antibacterial medicines used in routine infectious disease care.
Gynaecological and vaginal infection treatment
The sponsor is active in studies for bacterial vaginosis and vulvovaginal candidiasis, with focus on combined local therapies for specific and non-specific vaginitis.
- Vaginal pessaries
- Antifungal and antibacterial combinations
- Mycological and microbiological cure
Research in this area reflects interest in therapies for female reproductive tract infections and related local treatment options.
Bioequivalence of modified-release and prolonged-release medicines
Antibiotice S.A. funds comparative clinical research on its own formulations against established reference products, with emphasis on absorption and systemic exposure of orally administered medicines.
- Hard capsules and film-coated tablets
- Modified-release oral formulations
- Fed and fasting state comparisons
This area includes products designed for gastrointestinal, pain-related, and infectious disease indications.
Analgesic and gastroprotective combinations
The sponsor’s studies also involve naproxen combined with esomeprazole, indicating interest in therapies that pair anti-inflammatory action with acid suppression.
- Non-steroidal anti-inflammatory therapy
- Proton pump inhibitor combinations
- Upper gastrointestinal protection
These research activities align with medicines used in musculoskeletal pain and gastrointestinal risk management.
